Evidence map›Paper›PMID 40832110›Full record

ReviewFrontiers in dementia2025

Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer's disease treatment.

Xenia Androni, Rachel J Boyd, Paul B Rosenberg, Vasiliki Mahairaki

Abstract readReview
In one paragraph

Review in Frontiers in dementia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Xenia AndroniDepartment of Genetic Medicine, Johns Hopkins School of Medicine, Baltimore, MD, United States.
Rachel J BoydDepartment of Genetic Medicine, Johns Hopkins School of Medicine, Baltimore, MD, United States.
Paul B RosenbergThe Richman Family Precision Medicine Center of Excellence in Alzheimer's Disease, Johns Hopkins School of Medicine, Baltimore, MD, United States.
Vasiliki MahairakiDepartment of Genetic Medicine, Johns Hopkins School of Medicine, Baltimore, MD, United States.

Funding

Research Education ComponentP30AG066507 · NIA · JOHNS HOPKINS UNIVERSITY · PI Corinne Pettigrew · 2020 to 2026
$29.3M
NIA NIH HHS P30 AG066507
6 · The paper itself

Abstract

Alzheimer's disease (AD) is characterized by a long preclinical phase lasting more than a decade before the onset of its clinical phase of mild cognitive impairment (MCI) or dementia. Recent advances in psychedelic research underscore numerous neuroplastogenic and anti-inflammatory alterations induced by these compounds, making them promising therapeutic candidates for AD. In this mini review, we will briefly summarize the existing literature using human cerebral organoids to study the molecular and metabolic changes caused by various psychedelic compounds, focusing on their potential therapeutic applications for AD.

Indexed as

Alzheimer’s diseasebrain organoidsneuroplasticitypsychedelicsstem cells

Identifiers

PMID40832110
PMCPMC12358466

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.